Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment Total Payout Ratio Chart
Dar Al Dawa Development and Investment Annual Data
AMM:DADI vs ZTS, UTHR, VTRS: Total Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dar Al Dawa Development and Investment Total Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dar Al Dawa Development and Investment's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Dar Al Dawa Development and Investment's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment (AMM:DADI) has a Total Payout Ratio of -0.34 as of Aug. 04, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Dar Al Dawa Development and Investment and its competitors.
Is Dar Al Dawa Development and Investment's Total Payout Ratio too high?
Dar Al Dawa Development and Investment's current Total Payout Ratio is -0.34. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's Total Payout Ratio compare to ZTS and UTHR?
Dar Al Dawa Development and Investment's Total Payout Ratio of -0.34 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Drug Manufacturers company?
A good Total Payout Ratio depends on the Drug Manufacturers industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Dar Al Dawa Development and Investment and its competitors. Dar Al Dawa Development and Investment's current Total Payout Ratio is -0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD1.03, compared to a current price of JOD1.18 — trading 14.6% above its estimated fair value. The current Total Payout Ratio is -0.34. Dar Al Dawa Development and Investment's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current Total Payout Ratio is -0.34 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued.
The current stock price of JOD1.18 is trading 14.6% above its estimated GF Value™ of JOD1.03.
GuruFocus considers Dar Al Dawa Development and Investment to be Modestly Overvalued.
Key valuation signals for AMM:DADI:
Total Payout Ratio: -0.34
GF Value™: JOD1.03 vs. price of JOD1.18 (14.6% above fair value)
No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
77GF Score
Get the complete analysis for AMM:DADI
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:DADI has been successfully added to your 
